PP
LXRX icon

PDT Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

PDT Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-21,454
Closed -$98K – 847
2021
Q2 		$98K Sell
21,454
-5,106
-19% -$24.6K 0.01% 764
2021
Q1 		$156K Buy
+26,560
New +$184K 0.01% 720
2020
Q2 		– Sell
-170,500
Closed -$332K – 752
2020
Q1 		$332K Buy
+170,500
New +$508K 0.03% 456
2019
Q3 		– Sell
-142,600
Closed -$897K – 468
2019
Q2 		$897K Sell
142,600
-28,646
-17% -$171K 0.05% 263
2019
Q1 		$952K Buy
171,246
+16,745
+11% +$102K 0.05% 266
2018
Q4 		$1.03M Sell
154,501
-54,498
-26% -$442K 0.06% 270
2018
Q3 		$2.23M Sell
208,999
-29,300
-12% -$336K 0.09% 229
2018
Q2 		$2.86M Buy
238,299
+1,099
+0.5% +$11.2K 0.11% 214
2018
Q1 		$2.03M Sell
237,200
-897
-0.4% -$8.29K 0.07% 270
2017
Q4 		$2.35M Buy
+238,097
New +$2.47M 0.07% 276
2015
Q3 		– Sell
-20,845
Closed -$168K – 1441
2015
Q2 		$168K Buy
+20,845
New +$153K ﹤0.01% 1259

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PDT Partners's LXRX Position: Q3 2021 in Review

PDT Partners sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2021, closing a stake of 21,454 shares — an estimated $98K sold.

PDT Partners first reported a position in LXRX in Q2 2015 and held it in 11 quarters. The position peaked at $2.86M in Q2 2018. 96 funds tracked by Wall St. Rank hold LXRX as of Q3 2021.

  • PDT Partners reported no remaining Lexicon Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • PDT Partners sold 21,454 Lexicon Pharmaceuticals shares in Q3 2021, an estimated $98K.
  • PDT Partners first reported a position in Lexicon Pharmaceuticals in Q2 2015 and held it in 11 quarters.
  • PDT Partners's Lexicon Pharmaceuticals position peaked at $2.86M in Q2 2018.
  • 96 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.